CN101680014B - 分子的糖基化 - Google Patents

分子的糖基化 Download PDF

Info

Publication number
CN101680014B
CN101680014B CN200880018736.4A CN200880018736A CN101680014B CN 101680014 B CN101680014 B CN 101680014B CN 200880018736 A CN200880018736 A CN 200880018736A CN 101680014 B CN101680014 B CN 101680014B
Authority
CN
China
Prior art keywords
protein
glycosylation
activity
altered
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200880018736.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN101680014A (zh
Inventor
尼科·L·M·卡尔沃尔特
沃特·弗维肯
卡伦·J·马塞尔德波尔克
史蒂文·C·J·盖森斯
芒娜·古尔法尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxyrane UK Ltd
Original Assignee
Oxyrane UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxyrane UK Ltd filed Critical Oxyrane UK Ltd
Priority to CN201410681757.1A priority Critical patent/CN104480140B/zh
Publication of CN101680014A publication Critical patent/CN101680014A/zh
Application granted granted Critical
Publication of CN101680014B publication Critical patent/CN101680014B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2477—Hemicellulases not provided in a preceding group
    • C12N9/2488—Mannanases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01232—Initiation-specific alpha-1,6-mannosyltransferase (2.4.1.232)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01024—Alpha-mannosidase (3.2.1.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01046—Galactosylceramidase (3.2.1.46)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01084—Glucan 1,3-alpha-glucosidase (3.2.1.84), i.e. mutanase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01113—Mannosyl-oligosaccharide 1,2-alpha-mannosidase (3.2.1.113), i.e. alpha-1,2-mannosidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/52—Improvements relating to the production of bulk chemicals using catalysts, e.g. selective catalysts

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
CN200880018736.4A 2007-04-03 2008-04-03 分子的糖基化 Expired - Fee Related CN101680014B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201410681757.1A CN104480140B (zh) 2007-04-03 2008-04-03 分子的糖基化

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US90990407P 2007-04-03 2007-04-03
US60/909,904 2007-04-03
US94021207P 2007-05-25 2007-05-25
US60/940,212 2007-05-25
PCT/IB2008/001814 WO2008120107A2 (en) 2007-04-03 2008-04-03 Glycosylation of molecules

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201410681757.1A Division CN104480140B (zh) 2007-04-03 2008-04-03 分子的糖基化

Publications (2)

Publication Number Publication Date
CN101680014A CN101680014A (zh) 2010-03-24
CN101680014B true CN101680014B (zh) 2018-09-28

Family

ID=39808762

Family Applications (2)

Application Number Title Priority Date Filing Date
CN200880018736.4A Expired - Fee Related CN101680014B (zh) 2007-04-03 2008-04-03 分子的糖基化
CN201410681757.1A Expired - Fee Related CN104480140B (zh) 2007-04-03 2008-04-03 分子的糖基化

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201410681757.1A Expired - Fee Related CN104480140B (zh) 2007-04-03 2008-04-03 分子的糖基化

Country Status (9)

Country Link
US (5) US8026083B2 (cg-RX-API-DMAC7.html)
EP (4) EP2508614A3 (cg-RX-API-DMAC7.html)
JP (3) JP5967861B2 (cg-RX-API-DMAC7.html)
KR (3) KR20170091174A (cg-RX-API-DMAC7.html)
CN (2) CN101680014B (cg-RX-API-DMAC7.html)
CA (3) CA2887752C (cg-RX-API-DMAC7.html)
DK (2) DK2508612T3 (cg-RX-API-DMAC7.html)
SG (1) SG177941A1 (cg-RX-API-DMAC7.html)
WO (1) WO2008120107A2 (cg-RX-API-DMAC7.html)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1934605B1 (en) * 2005-09-22 2014-03-26 Prosci Incorporated Glycosylated polypeptides produced in yeast mutants and methods of use thereof
KR20090074040A (ko) 2006-09-13 2009-07-03 아보트 러보러터리즈 세포 배양의 개선
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
KR20170091174A (ko) 2007-04-03 2017-08-08 옥시레인 유케이 리미티드 분자의 글리코실화
EP2137655B1 (en) * 2007-04-16 2012-07-11 Momenta Pharmaceuticals, Inc. Defined glycoprotein products and related methods
AU2009202778B2 (en) * 2008-07-11 2014-05-08 Commonwealth of Australia as represented by and acting through the Department of Climate Change, Energy, the Environment and Water Improved baiting method and composition
AU2009307737B2 (en) 2008-10-20 2015-07-23 Abbvie Inc. Viral inactivation during purification of antibodies
EP2350127B1 (en) * 2008-10-20 2015-01-28 AbbVie Inc. Isolation and purification of antibodies using protein a affinity chromatography
WO2011011495A1 (en) * 2009-07-24 2011-01-27 Merck Sharp & Dohme Corp. Recombinant ectodomain expression of herpes simplex virus glycoproteins in yeast
ES2783024T3 (es) 2009-09-29 2020-09-16 Univ Gent Hidrólisis de la unión de manosa-1-fosfo-6-manosa a fosfo-6-manosa
DK2501805T3 (en) 2009-11-19 2019-04-15 Oxyrane Uk Ltd Yeast strains producing mammalian-like complex N-Glycans
MX2012009802A (es) * 2010-02-24 2012-09-12 Merck Sharp & Dohme Metodo para incrementar la ocupacion del sitio de n-glucosilacion en glucoproteinas terapeuticas producidas en pichia pastoris.
WO2011119498A1 (en) * 2010-03-22 2011-09-29 Tetragenetics, Inc. Production of glycoproteins in genetically modified ciliates
BR112012025654A2 (pt) * 2010-04-07 2017-07-18 Momenta Pharmaceuticals Inc seleção e uso de células hospedeiras para produção de glicoproteína
AU2011237442A1 (en) 2010-04-07 2012-10-18 Momenta Pharmaceuticals, Inc. High mannose glycans
AU2011282988A1 (en) * 2010-07-28 2013-01-31 Smartcells, Inc. Recombinantly expressed insulin polypeptides and uses thereof
CA2812872C (en) * 2010-09-29 2021-08-03 Oxyrane Uk Limited De-mannosylation of phosphorylated n-glycans
CN103328646B (zh) * 2010-09-29 2021-06-18 奥克西雷恩英国有限公司 能够使甘露糖-1-磷酸-6-甘露糖连接脱帽并使磷酸化的n-聚糖脱甘露糖基化的甘露糖苷酶及促进糖蛋白的哺乳动物细胞摄取的方法
EP2686671A4 (en) 2011-03-12 2015-06-24 Momenta Pharmaceuticals Inc N-GLYCANES CONTAINING N-ACETYLHEXOSAMINE IN GLYCOPROTEIN PRODUCTS
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9567596B2 (en) * 2012-01-05 2017-02-14 Glykos Finland Oy Protease deficient filamentous fungal cells and methods of use thereof
KR20190114003A (ko) 2012-03-15 2019-10-08 옥시레인 유케이 리미티드 폼페병의 치료를 위한 방법 및 물질
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
US9695244B2 (en) 2012-06-01 2017-07-04 Momenta Pharmaceuticals, Inc. Methods related to denosumab
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
WO2014035475A1 (en) 2012-09-02 2014-03-06 Abbvie Inc. Methods to control protein heterogeneity
CN102965292A (zh) * 2012-12-10 2013-03-13 江南大学 一种葡萄糖氧化酶分泌增强型菌株及其应用
US20190040368A1 (en) 2013-03-05 2019-02-07 Oxyrane Uk Limited Production of catalytically active type i sulfatase
CA2905010A1 (en) 2013-03-12 2014-09-18 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
EP2855533A4 (en) 2013-03-15 2015-11-25 Momenta Pharmaceuticals Inc METHODS RELATING TO CTLA4-FC FUSION PROTEINS
AR095615A1 (es) * 2013-03-15 2015-10-28 Alder Biopharmaceuticals Inc Purificación de anticuerpos y monitoreo de pureza
EP2789686A1 (en) 2013-04-11 2014-10-15 Greenovation Biotech GmbH Expression of phosphorylated glycoproteins in plants
WO2014177771A1 (en) 2013-05-02 2014-11-06 Glykos Finland Oy Conjugates of a glycoprotein or a glycan with a toxic payload
WO2014186310A1 (en) 2013-05-13 2014-11-20 Momenta Pharmaceuticals, Inc. Methods for the treatment of neurodegeneration
EP3041949B1 (en) 2013-09-05 2021-04-28 Vib Vzw Cells producing fc containing molecules having altered glycosylation patterns and methods and use thereof
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
WO2015057622A1 (en) 2013-10-16 2015-04-23 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
TWI793159B (zh) * 2013-10-23 2023-02-21 美商健臻公司 重組醣蛋白及其用途
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2016012468A1 (en) 2014-07-21 2016-01-28 Novartis Ag Production of glycoproteins with mammalian-like n-glycans in filamentous fungi
KR101750888B1 (ko) * 2014-09-23 2017-06-26 한국생명공학연구원 YlMpo1 과발현을 이용한 만노스인산화 증대 방법
AU2016226418B2 (en) 2015-03-02 2022-05-26 Synthetic Genomics, Inc. Regulatory elements from labyrinthulomycetes microorganisms
CN104849474A (zh) * 2015-05-17 2015-08-19 先思达（南京）生物科技有限公司 一种阿兹海默病的生物标记检测方法
EP3393501B1 (en) 2015-12-24 2023-06-07 Oxyrane UK Limited Human alpha-n-acetylgalactosaminidase polypeptide
EP3432902B8 (en) * 2016-03-20 2025-12-17 The Trustees of The University of Pennsylvania Codon optimization and ribosome profiling for increasing transgene expression in chloroplasts of higher plants
US10633454B2 (en) 2016-11-01 2020-04-28 Conagen Inc. Expression of modified glycoproteins and glycopeptides
EP3535385A4 (en) * 2016-11-01 2020-06-17 Conagen Inc. EXPRESSION OF MODIFIED GLYCOPROTEINS AND GLYCOPEPTIDES
WO2020073734A1 (zh) * 2018-10-12 2020-04-16 深圳市真迈生物科技有限公司 一种生物芯片及其制备方法
EP3917558A1 (en) 2019-02-01 2021-12-08 Oxyrane UK Limited Glucocerebrosidase polypeptides
HRP20240184T1 (hr) 2019-02-04 2024-04-26 Freeline Therapeutics Limited Polinukleotidi
CN110128540B (zh) * 2019-04-18 2021-12-14 江南大学 一种基于便携式血糖仪的二抗
CN110499259B (zh) * 2019-07-22 2021-07-27 浙江工业大学 一种解酯耶氏酵母yw100-1及其应用
KR102477054B1 (ko) * 2020-03-24 2022-12-14 주식회사 바이오앱 웅취 제거용 재조합 단백질 및 이를 포함하는 백신 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003056914A1 (en) * 2001-12-27 2003-07-17 Glycofi, Inc. Methods to engineer mammalian-type carbohydrate structures

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4307717A (en) 1977-11-07 1981-12-29 Lectec Corporation Sterile improved bandage containing a medicament
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4352883A (en) 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
JPS5754588A (en) 1980-09-19 1982-04-01 Eiji Ichijima Alpha-mannosidase
US4353888A (en) 1980-12-23 1982-10-12 Sefton Michael V Encapsulation of live animal cells
US4407957A (en) 1981-03-13 1983-10-04 Damon Corporation Reversible microencapsulation of a core material
US4837148A (en) 1984-10-30 1989-06-06 Phillips Petroleum Company Autonomous replication sequences for yeast strains of the genus pichia
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4882279A (en) 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
US4883666A (en) 1987-04-29 1989-11-28 Massachusetts Institute Of Technology Controlled drug delivery system for treatment of neural disorders
US4929555A (en) 1987-10-19 1990-05-29 Phillips Petroleum Company Pichia transformation
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
DE3829752A1 (de) 1988-09-01 1990-03-22 Akzo Gmbh Integrale asymmetrische polyaethersulfonmembran, verfahren zur herstellung und verwendung zur ultrafiltration und mikrofiltration
DE3829766A1 (de) 1988-09-01 1990-03-22 Akzo Gmbh Verfahren zur herstellung von membranen
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5084350A (en) 1990-02-16 1992-01-28 The Royal Institution For The Advance Of Learning (Mcgill University) Method for encapsulating biologically active material including cells
US5272070A (en) 1991-03-08 1993-12-21 Board Of Regents, The University Of Texas System Method for the preparation of cell lines producing Man3 GlcNac 2 asparagine-linked gylcans and cell lines produced thereby
ES2107537T3 (es) 1991-04-25 1997-12-01 Univ Brown Res Found Vehiculo inmunoaislante biocompatible implantable para suministrar productos terapeuticos seleccionados.
US5733761A (en) 1991-11-05 1998-03-31 Transkaryotic Therapies, Inc. Protein production and protein delivery
US6042828A (en) 1992-09-07 2000-03-28 Kyowa Hakko Kogyo Co., Ltd. Humanized antibodies to ganglioside GM2
EP1179350A3 (en) 1993-08-12 2003-01-02 Cytotherapeutics, Inc. Encapsulated cell system for implantation into the human CNS
US5589359A (en) 1994-08-05 1996-12-31 Chiron Corporation Chimeric proteins
US5834251A (en) 1994-12-30 1998-11-10 Alko Group Ltd. Methods of modifying carbohydrate moieties
AU2887897A (en) 1996-05-21 1997-12-09 Novo Nordisk A/S Novel yeast promoters suitable for expression cloning in yeast and heterologous expression of proteins in yeast
US6300065B1 (en) 1996-05-31 2001-10-09 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
WO1998001473A1 (en) 1996-07-05 1998-01-15 Novo Nordisk A/S Method for the production of precursors of insulin, precursors of insulin analogues, and insulin like peptides
US6110703A (en) 1996-07-05 2000-08-29 Novo Nordisk A/S Method for the production of polypeptides
WO1998001535A1 (en) 1996-07-05 1998-01-15 Novo Nordisk A/S Method for the production of polypeptides
PT975775E (pt) 1997-04-23 2004-07-30 Vlaams Interuniv Inst Biotech Sistema regulador para a expressao induzivel de genes com promotores lambdoides
US7442772B2 (en) 1997-12-03 2008-10-28 Genentech, Inc. Antibodies to PRO361 polypeptide
AU2241699A (en) 1998-01-27 1999-08-09 Board Of Regents Of The University And Community College System Of Nevada, The Expression of proteolytically-sensitive peptides
WO2001042462A2 (en) 1999-12-08 2001-06-14 National University Of Singapore Phospholipase a2 inhibitory peptides from python reticulatus
WO2001049830A2 (en) 1999-12-30 2001-07-12 Maxygen Aps Improved lysosomal enzymes and lysosomal enzyme activators
AU2001256762A1 (en) 2000-05-17 2001-11-26 Mitsubishi Pharma Corporation Process for producing protein with reduction of acidic sugar chain and glycoprotein produced thereby
US7625756B2 (en) 2000-06-28 2009-12-01 GycoFi, Inc. Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells
US7598055B2 (en) 2000-06-28 2009-10-06 Glycofi, Inc. N-acetylglucosaminyltransferase III expression in lower eukaryotes
US7863020B2 (en) 2000-06-28 2011-01-04 Glycofi, Inc. Production of sialylated N-glycans in lower eukaryotes
MXPA03000105A (es) 2000-06-28 2004-09-13 Glycofi Inc Metodo para producir glicoproteinas modificadas.
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US8697394B2 (en) 2000-06-28 2014-04-15 Glycofi, Inc. Production of modified glycoproteins having multiple antennary structures
US7795002B2 (en) 2000-06-28 2010-09-14 Glycofi, Inc. Production of galactosylated glycoproteins in lower eukaryotes
AU2001277658B2 (en) 2000-06-30 2006-10-19 Research Corporation Technologies, Inc. Protein glycosylation modification in pichia pastoris
KR100386836B1 (ko) 2000-08-31 2003-06-09 동국제약 주식회사 재조합 인체 부갑상선 호르몬을 생산하는 형질전환효모 및재조합 인체 부갑상선 호르몬의 생산방법
US7001994B2 (en) * 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
JP4742191B2 (ja) 2001-06-14 2011-08-10 独立行政法人産業技術総合研究所 糖蛋白質およびその製造方法
US20030186374A1 (en) 2001-10-01 2003-10-02 Hufton Simon E. Multi-chain eukaryotic display vectors and uses thereof
US7473680B2 (en) * 2001-11-28 2009-01-06 Neose Technologies, Inc. Remodeling and glycoconjugation of peptides
DK1527100T3 (da) 2002-03-29 2009-09-07 Schering Corp Humane monoklonale antistoffer mod interleukin-5 og fremgangsm der og sammens tninger omfattende samme
WO2003091431A1 (en) 2002-04-26 2003-11-06 Kirin Beer Kabushiki Kaisha Methylotroph producing mammalian type sugar chain
IL165717A0 (en) 2002-06-26 2006-01-15 Flanders Interuniversity Inst A strain of methylotrophic yeast for producing proteins
ATE480624T1 (de) 2002-06-29 2010-09-15 Korea Res Inst Of Bioscience Yapsin-mangelmutantenstamm von hansenula polymorpha sowie verfahren zur herstellung rekombinanter proteine damit
KR100470978B1 (ko) 2003-01-02 2005-03-10 한국생명공학연구원 앱신 다중 결손 효모 변이 균주 및 이를 이용한 재조합 단백질의 생산 방법
AU2012206984B2 (en) 2003-02-11 2015-07-09 Takeda Pharmaceutical Company Limited Diagnosis and treatment of multiple sulfatase deficiency and other using a formylglycine generating enzyme (FGE)
JP4259169B2 (ja) 2003-04-16 2009-04-30 昭和産業株式会社 新規α−１，２−マンノシダーゼおよびその遺伝子、ならびに該酵素を用いたα−マンノシル糖化合物の製造方法
US7259255B2 (en) 2003-06-25 2007-08-21 E. I. Du Pont De Nemours And Company Glyceraldehyde-3-phosphate dehydrogenase and phosphoglycerate mutase promoters for gene expression in oleaginous yeast
ES2528739T3 (es) 2003-12-24 2015-02-12 Glycofi, Inc. Métodos para eliminar la manosilfosforilación de glucanos en la producción de glucoproteínas
US20050244400A1 (en) * 2004-02-10 2005-11-03 Zystor Therapeutics, Inc. Acid alpha-glucosidase and fragments thereof
WO2005089047A2 (en) 2004-03-18 2005-09-29 Glycofi, Inc. Glycosylated glucocerebrosidase expression in fungal hosts
CA2562772A1 (en) 2004-04-15 2005-10-27 Glycofi, Inc. Production of galactosylated glycoproteins in lower eukaryotes
CA2501422C (en) 2004-04-29 2014-08-12 University Of Rochester Lymphoid chemokines in the diagnosis, monitoring and treatment of autoimmune disease
US7465577B2 (en) 2004-04-29 2008-12-16 Glycofi, Inc. Methods for reducing or eliminating α-mannosidase resistant glycans for the production of glycoproteins
US20060014264A1 (en) 2004-07-13 2006-01-19 Stowers Institute For Medical Research Cre/lox system with lox sites having an extended spacer region
US7431927B2 (en) 2005-03-24 2008-10-07 Epitomics, Inc. TNFα-neutralizing antibodies
CA2604917A1 (en) 2005-04-14 2007-01-25 Csir Recombinant yeasts for synthesizing epoxide hydrolases
ATE493652T1 (de) * 2005-08-11 2011-01-15 Siemens Healthcare Diagnostics Quantitative assays für pdgfr-beta- in körperflüssigkeiten
EP1934605B1 (en) * 2005-09-22 2014-03-26 Prosci Incorporated Glycosylated polypeptides produced in yeast mutants and methods of use thereof
US8232377B2 (en) * 2006-05-16 2012-07-31 National Institute Of Advanced Industrial Science And Technology Method for high-level secretory production of protein
US20080081035A1 (en) 2006-10-03 2008-04-03 National Enzyme Company Therapeutic protease compositions
CA2677383A1 (en) 2007-02-09 2008-08-21 Medimmune, Llc Antibody library display by yeast cell plasma membrane
KR20170091174A (ko) * 2007-04-03 2017-08-08 옥시레인 유케이 리미티드 분자의 글리코실화
WO2008143354A1 (ja) 2007-05-18 2008-11-27 Tokyo Metropolitan Organization For Medical Research 酵素補充療法用医薬組成物
EP2189014B1 (en) 2007-09-14 2014-06-25 Unwired Planet International Limited User data notification in a mobile communications system
PL2245145T3 (pl) 2008-01-18 2017-07-31 Biomarin Pharmaceutical Inc. Wytwarzanie aktywnych wysoce fosforylowanych ludzkich enzymów sulfatazy lizosomalnej i ich zastosowania
CA2723412A1 (en) 2008-05-07 2009-11-12 Zystor Therapeutics, Inc. Lysosomal targeting peptides and uses thereof
WO2010099195A1 (en) 2009-02-26 2010-09-02 Glaxosmithkline Llc. Host cells and methods of use
ES2783024T3 (es) 2009-09-29 2020-09-16 Univ Gent Hidrólisis de la unión de manosa-1-fosfo-6-manosa a fosfo-6-manosa
DK2501805T3 (en) * 2009-11-19 2019-04-15 Oxyrane Uk Ltd Yeast strains producing mammalian-like complex N-Glycans
FR2954349A1 (fr) 2009-12-22 2011-06-24 Agronomique Inst Nat Rech Sulfatase modifiant selectivement les glycosaminoglycanes
WO2011089527A1 (en) 2010-01-21 2011-07-28 Oxyrane Uk Limited Methods and compositions for displaying a poypeptide on a yeast cell surface
US20120135461A1 (en) 2010-07-30 2012-05-31 William James Cook Production of glycoproteins with reduced o-glycosylation comprising the use of an alpha-1,2-mannosidase
CN103328646B (zh) 2010-09-29 2021-06-18 奥克西雷恩英国有限公司 能够使甘露糖-1-磷酸-6-甘露糖连接脱帽并使磷酸化的n-聚糖脱甘露糖基化的甘露糖苷酶及促进糖蛋白的哺乳动物细胞摄取的方法
CA2812872C (en) * 2010-09-29 2021-08-03 Oxyrane Uk Limited De-mannosylation of phosphorylated n-glycans
CN104136622A (zh) 2011-12-30 2014-11-05 奥克西雷恩英国有限公司 用于降低重组蛋白的降解的方法和材料
KR20190114003A (ko) * 2012-03-15 2019-10-08 옥시레인 유케이 리미티드 폼페병의 치료를 위한 방법 및 물질

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003056914A1 (en) * 2001-12-27 2003-07-17 Glycofi, Inc. Methods to engineer mammalian-type carbohydrate structures

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Identification and characterization of two a-1,6-mannosyltransferases, Anl1p and Och1p, in the yeast Yarrowia lipolytica;Stephanie Barnay-Verdier等;《Microbiology》;20041231;2185-2195 *

Also Published As

Publication number Publication date
US9206408B2 (en) 2015-12-08
US20090069232A1 (en) 2009-03-12
EP2508612A3 (en) 2013-08-14
WO2008120107A3 (en) 2009-05-14
US20110201540A1 (en) 2011-08-18
JP6228096B2 (ja) 2017-11-08
US8026083B2 (en) 2011-09-27
JP2015006205A (ja) 2015-01-15
SG177941A1 (en) 2012-02-28
JP6511476B2 (ja) 2019-05-15
EP2508613A2 (en) 2012-10-10
US20130190253A1 (en) 2013-07-25
KR20100016181A (ko) 2010-02-12
US20130195835A1 (en) 2013-08-01
WO2008120107A2 (en) 2008-10-09
CA2887752C (en) 2020-03-24
JP2017060528A (ja) 2017-03-30
US20110207676A1 (en) 2011-08-25
CA2887752A1 (en) 2008-10-09
CN101680014A (zh) 2010-03-24
KR20160003316A (ko) 2016-01-08
CA2682578A1 (en) 2008-10-09
EP2508612A2 (en) 2012-10-10
CN104480140A (zh) 2015-04-01
DK2508612T3 (en) 2018-01-22
DK2134853T3 (en) 2018-10-08
EP2134853A2 (en) 2009-12-23
KR101811057B1 (ko) 2017-12-20
EP2134853B1 (en) 2018-07-18
EP2508613A3 (en) 2012-11-28
KR101812400B1 (ko) 2017-12-27
US10023854B2 (en) 2018-07-17
JP5967861B2 (ja) 2016-08-10
EP2508614A3 (en) 2012-11-28
US9222083B2 (en) 2015-12-29
EP2508614A2 (en) 2012-10-10
JP2010523102A (ja) 2010-07-15
CA3069431A1 (en) 2008-10-09
EP2508612B1 (en) 2017-11-29
KR20170091174A (ko) 2017-08-08
CN104480140B (zh) 2019-12-31
CA2682578C (en) 2015-05-26
US8597906B2 (en) 2013-12-03

Similar Documents

Publication Publication Date Title
CN101680014B (zh) 分子的糖基化
CA2490268C (en) Protein glycosylation modification in pichia pastoris
JP2010523102A5 (cg-RX-API-DMAC7.html)
EP2501805B1 (en) Yeast strains producing mammalian-like complex n-glycans
US9689015B2 (en) De-mannosylation of phosphorylated N-glycans
JP2012506710A (ja) 宿主細胞中での糖鎖付加タンパク質の産生のための新規ツール
KR20140091018A (ko) 재조합 단백질 발현을 위한 조작된 하등 진핵 숙주 균주
CA2762982A1 (en) Glycosylation of molecules
HK1169680B (en) Glycosylation of molecules
HK1138041A (en) Glycosylation of molecules
HK1138041B (en) Glycosylation of molecules
HK1169680A (en) Glycosylation of molecules

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: University of Manchester

Applicant after: OXYRANE UK Ltd.

Address before: University of Manchester

Applicant before: Oxyrane UK. Ltd.

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: OXYRANE UK. LTD. TO: OXYRANE UK LTD.

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20180928